GSC000580

GSC000580: sourced facts only. name: "In vitro, GSC000580 could bind to MC4R receptor with less than 1nM potency with high (500∼1000 fold) selectivity across the melanocortin receptor family and potently blocking cAMP production with less than 1nM potency in cellular functional assay." [DOI:10.1158/1538-7445.am2025-6913]; target: "In vitro, GSC000580 could bind to MC4R receptor with less than 1nM potency with high (500∼1000 fold) selectivity across the melanocortin receptor family and potently blocking cAMP production with less than 1nM potency in cellular functional assay." [DOI:10.1158/1538-7445.am2025-6913]; developer: "Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2025-6913]; modality: "Discovery of GSC000580, a novel oral small molecule of MC4R antagonist for treatment of cancer-related body mass loss" [DOI:10.1158/1538-7445.am2025-6913]; stage: "In vivo, GSC000580 demonstrated dose-dependent significant increase of body weight gain and food intake in cisplatin-induced and aging-related anorexia rat models." [DOI:10.1158/1538-7445.am2025-6913]